NCT05268237View on ClinicalTrials.gov

Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Diabete Type 2
Interventions
DRUG

Liraglutide

Sublingual or subcutaneous liraglutide

DRUG

Placebo

Sublingual placebo

Trial Locations (1)

Unknown

RECRUITING

Clinical Trials Unit, Chinese University of Hong Kong, Hong Kong

Sponsors

Lead Sponsor

Biolingus
All Listed Sponsors
collaborator

Chinese University of Hong Kong

OTHER

lead

Biolingus

INDUSTRY

NCT05268237 - Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter